BioPharmX (NYSEAMERICAN:BPMX) reports fiscal Q1 2020 financial results

Start trading
Updated: 13 June 2019
  • BioPharmX Corporation (NYSEAMERICAN:BPMX) reported its Q1 2020 financial results (quarter that ended 30th April 2019);
  • The company reported a reduction in both GAAP and non-GAAP net losses;
  • BioPharmX also reported a reduction in total operating expenses.

BioPharmX Corporation has reported its Q1 2020 financial results. The pharmaceutical company reported a reduction in net losses (both GAAP and non-GAAP net losses) as well as less operating expenses than compared to the previous year.

BioPharmX’s total operating expenses were $3.6m, which is down from the $4.4m reported in the same quarter of 2018.

Net losses were reported at $3.6m versus the previous year’s result of $4.4m. When converted into a per-share basis, this year’s net loss comes out at $0.38 per share while the previous year’s result was $0.61 per share. Non-GAAP net losses are $0.36 per share versus the previous year’s $0.52 per share.